Clinical Trial Update: Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a conditioning regimen of busulfan, melphalan, and bortezomib before first-line stem cell transplant in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Busulfan, Melphalan, and Bortezomib

Snippet

Sponsor: Albert Einstein College of Medicine | Conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-08-20